Earnings ·
Monte Rosa Therapeutics reported second quarter 2026 financial results on August 6, 2026
GLUEMonte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics reported second quarter 2026 financial results on August 6, 2026. The company posted a net loss of $43.4 million compared to $12.3 million in the prior year period. Collaboration revenue decreased to $9.0 million from $23.2 million. Research and development expenses rose to $48.0 million due to increased spending on the MRT-8102 program, while general and administrative expenses increased to $10.1 million. The company ended the quarter with a strong balance sheet holding $626.0 million in cash and marketable securities, which is expected to fund operations into 2029. Clinically, Monte Rosa completed enrollment for the GFORCE-1 study of MRT-8102 and activated Phase 2 trials for MRT-2359 in prostate cancer and MRT-6160 in Sjögren’s disease through its Novartis collaboration. Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader medicines.